MNPR

Monopar Therapeutics Inc. (MNPR) | Rumor.io

Monopar Therapeutics

MNPR

Attention (50-day avg)0%

Attention rank (50-day avg)#3,191

Bullish sentiment (50-day avg)25%

Price to earnings ratio-45.1

Market capitalization561.9M

Earnings per share-2.2

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13.7M

Social

What share of all stock conversation is about MNPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 10

Monopar Therapeutics Inc. ($MNPR) reported positive Phase 2 study results for ALXN1840 in treating Wilson disease, showing significant improvements in copper balance due to increased fecal copper excretion.
The company presented new data from its Phase 2 copper balance study at the AASLD Liver Meeting 2025, highlighting significant findings in liver disease research and a rapid and sustained improvement in daily copper balance for patients treated with ALXN1840.
Analysts have updated their ratings for Monopar Therapeutics, with Leerink Partners upgrading to Outperform and setting a price target of $115, and Chardan Capital upgrading to Buy with a target set at $100.

Generated by AI

Sentiment

Of the messages about MNPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	76.22% +3.01
Bearish	—	—	—	23.78% -3.01

Bullish· Oct 31

The CFO's recent purchase of 1550 shares at $16.25 may indicate confidence in the company's future prospects.
The asset's price is expected to increase following a potential news announcement, with some users predicting a surge to $18 or higher.
The company's "beautiful" spread and the recent volume influx may create opportunities for buyers to scoop up shares at a lower price.

Bearish· Oct 31

$MNPR is experiencing a significant decline, with some investors expecting it to drop back to $5.
The CFO's recent purchase at $16.25 may indicate a lack of confidence in the company's prospects, with some investors expecting a further decline.
The stock's volume is weak, with some investors attributing this to a lack of interest in the company, possibly due to big investors waiting for the post-election period.

Generated by AI

Topics

Of the messages about MNPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	71.57%
Analysts	—	—	100%	17.73%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	10.7%

Announcements· Oct 29

Monopar Therapeutics Inc. ($MNPR) has announced a public offering of 1,181,540 shares of common stock at $16.25 per share, raising approximately $19.2 million in gross proceeds.
The offering was led by Rodman & Renshaw as the sole book-running manager, with the funds intended to support Monopar's ongoing research and development, including its collaboration with AstraZeneca (ALXN).
The successful public offering demonstrates Monopar's ability to access capital markets and positions the company for potential advancements in cancer treatments and revenue growth.

Technical Analysis· Oct 25

$MNPR may test $30 or higher soon, with potential support at $20 and resistance at $38-$61.66.
Technical analysis suggests a bullish cup and handle formation, with a possible break above $38 and a new high.
The stock is trending upwards, with a break above the Volume Weighted Average Price, and may retest $38 or dip to $16.50 if support levels are broken.

Generated by AI

Community

Of the messages about MNPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	83.33%	16.08%
Newcomers	—	—	16.67%	83.92%

Regulars· Oct 29

The $19.2M public offering of Monopar Therapeutics Inc. common stock was priced at $16.25 per share.
Monopar Therapeutics has retrieved a Wilson disease candidate from AstraZeneca's scrap heap, potentially reviving the project.
The company's stock price has declined due to the dilution of existing shareholders from the public offering.

Newcomers· Oct 29

Monopar Therapeutics Inc. (MNPR) has secured legitimate funding from blue-chip biotech specialists funds at a valuation multiple times higher than its previous value.
The company announced a public offering of common stock, priced at $16.25 per share, with Rodman & Renshaw serving as the sole book-running manager.
AstraZeneca has a 9.9% stake in Monopar Therapeutics Inc. (MNPR) and would need to be paid $4M if the company were to stop working with them.

Generated by AI

News

Also Discussed

Investors talking about MNPR also mention

#	Name	Attention
1	TBIO - Telesis Bio, Inc.	——
2	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
3	Bright Minds Biosciences Inc.DRUG	0%new
4	CytoMed Therapeutics Ltd.GDTC	0%0
5	Radiopharm Theranostics Limited Depositary ReceiptRADX	0%new
6	Amaze Holdings, Inc.VINE	0%new
7	Simpple Ltd.SPPL	0%new
8	Tevogen Bio Holdings Inc.TVGN	0%0
9	Earlyworks Co., Ltd. ADRELWS	0%0
10	Neo-Concept International Group Holdings Limited Class A Ordinary SharesNCI	0.01%+0.01

Monopar Therapeutics Inc.

Healthcare
Biotechnology

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancer and rare diseases. Its current work centers on novel radiopharmaceuticals for oncology, antibody-based programs, and other proprietary therapies designed to address serious conditions with limited treatment options. The company’s pipeline includes candidates aimed at advanced cancers, such as soft tissue sarcoma and other hard-to-treat oncology settings, as well as a treatment program for Wilson disease, a rare genetic disorder. Monopar Therapeutics Inc. operates as a research-driven drug developer, advancing its assets through preclinical and clinical development rather than commercial product sales. Based in Wilmette, Illinois and founded in 2014, Monopar Therapeutics Inc. plays a specialized role in the healthcare market by pursuing innovative therapies for patients with significant unmet medical needs.

Website

Location

1000 Skokie Boulevard

Wilmette, IL, 60091

United States

Social

What share of all stock conversation is about MNPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 10

Monopar Therapeutics Inc. ($MNPR) reported positive Phase 2 study results for ALXN1840 in treating Wilson disease, showing significant improvements in copper balance due to increased fecal copper excretion.
The company presented new data from its Phase 2 copper balance study at the AASLD Liver Meeting 2025, highlighting significant findings in liver disease research and a rapid and sustained improvement in daily copper balance for patients treated with ALXN1840.
Analysts have updated their ratings for Monopar Therapeutics, with Leerink Partners upgrading to Outperform and setting a price target of $115, and Chardan Capital upgrading to Buy with a target set at $100.

Generated by AI

Sentiment

Of the messages about MNPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	76.22% +3.01
Bearish	—	—	—	23.78% -3.01

Bullish· Oct 31

The CFO's recent purchase of 1550 shares at $16.25 may indicate confidence in the company's future prospects.
The asset's price is expected to increase following a potential news announcement, with some users predicting a surge to $18 or higher.
The company's "beautiful" spread and the recent volume influx may create opportunities for buyers to scoop up shares at a lower price.

Bearish· Oct 31

$MNPR is experiencing a significant decline, with some investors expecting it to drop back to $5.
The CFO's recent purchase at $16.25 may indicate a lack of confidence in the company's prospects, with some investors expecting a further decline.
The stock's volume is weak, with some investors attributing this to a lack of interest in the company, possibly due to big investors waiting for the post-election period.

Generated by AI

Topics

Of the messages about MNPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	71.57%
Analysts	—	—	100%	17.73%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	10.7%

Announcements· Oct 29

Monopar Therapeutics Inc. ($MNPR) has announced a public offering of 1,181,540 shares of common stock at $16.25 per share, raising approximately $19.2 million in gross proceeds.
The offering was led by Rodman & Renshaw as the sole book-running manager, with the funds intended to support Monopar's ongoing research and development, including its collaboration with AstraZeneca (ALXN).
The successful public offering demonstrates Monopar's ability to access capital markets and positions the company for potential advancements in cancer treatments and revenue growth.

Technical Analysis· Oct 25

$MNPR may test $30 or higher soon, with potential support at $20 and resistance at $38-$61.66.
Technical analysis suggests a bullish cup and handle formation, with a possible break above $38 and a new high.
The stock is trending upwards, with a break above the Volume Weighted Average Price, and may retest $38 or dip to $16.50 if support levels are broken.

Generated by AI

Community

Of the messages about MNPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	83.33%	16.08%
Newcomers	—	—	16.67%	83.92%

Regulars· Oct 29

The $19.2M public offering of Monopar Therapeutics Inc. common stock was priced at $16.25 per share.
Monopar Therapeutics has retrieved a Wilson disease candidate from AstraZeneca's scrap heap, potentially reviving the project.
The company's stock price has declined due to the dilution of existing shareholders from the public offering.

Newcomers· Oct 29

Monopar Therapeutics Inc. (MNPR) has secured legitimate funding from blue-chip biotech specialists funds at a valuation multiple times higher than its previous value.
The company announced a public offering of common stock, priced at $16.25 per share, with Rodman & Renshaw serving as the sole book-running manager.
AstraZeneca has a 9.9% stake in Monopar Therapeutics Inc. (MNPR) and would need to be paid $4M if the company were to stop working with them.

Generated by AI

Monopar Therapeutics

Social

Nov 10

Bullish· Oct 31

Bearish· Oct 31

Announcements· Oct 29

Technical Analysis· Oct 25

Regulars· Oct 29

Newcomers· Oct 29

Monopar Therapeutics CEO Robinson sells $2.5m in stock

Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares

Monopar Therapeutics director Raymond Anderson sells $351,835 in stock

Monopar Therapeutics director Raymond Anderson sells $351k in stock

Monopar director Kim Tsuchimoto sells $455k in common stock

Monopar Therapeutics acting CMO sells $111 of stock, exercises options

Also Discussed

Monopar Therapeutics Inc.

Company Information

Location

Monopar Therapeutics CEO Robinson sells $2.5m in stock

Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares

Monopar Therapeutics director Raymond Anderson sells $351,835 in stock

Monopar Therapeutics director Raymond Anderson sells $351k in stock

Monopar director Kim Tsuchimoto sells $455k in common stock

Monopar Therapeutics acting CMO sells $111 of stock, exercises options

Also Discussed

Social

Nov 10

Bullish· Oct 31

Bearish· Oct 31

Announcements· Oct 29

Technical Analysis· Oct 25

Regulars· Oct 29

Newcomers· Oct 29